Table 3.

Promising targets and inhibitors for hepatoblastoma

Target	Inhibitor
mTOR	Rapamycin, polyphyllin VII
PI3K	LY294002
Akt	Emodin, FTY720, furazolidone
β-catenin	Celecoxib, R-etodolac, ICG001, miR-624-5p, let-7i-3p, miR-885-5p
NK1R	Aprepitant, L-733060, L-732138
EpCAM/CD326	Catumaxomab, IGN101, MT110
GPC3	Codrituzumab, vaccines EYILSLEEL and FVGEFFTDV

Akt, serine-threonine kinase; EpCAM/CD326, epithelial cell adhesion molecule; FTY720, fingolimod; GPC3, glypican-3; ICG001, (6S,9aS)-6-(4-hydroxybenzyl)-N-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-hexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide; IGN101, Al(OH)3-formulated Mab17-1A; LY294002, (2)-4-morpholinyl 8-phenyl-4h-1-benzopyran-4-one; MT110, solitomab; mTOR, mammalian target of rapamycin; NK1R, neurokinin receptor; PI3K, phosphodylinositol 3-kinase.